SCHEDULE: Paradigm BioCapital Discloses Stake in Spyre Therapeutics

Paradigm BioCapital Advisors LP, along with affiliated entities, has reported beneficial ownership of 5.1% of Spyre Therapeutics, Inc. common stock.

Summary

• Paradigm BioCapital Advisors LP, Paradigm BioCapital Advisors GP LLC, Senai Asefaw, M.D., and Paradigm BioCapital International Fund Ltd. have jointly filed a Schedule 13G.
• This filing indicates beneficial ownership of Spyre Therapeutics, Inc. common stock.
• The total aggregate amount beneficially owned by the reporting persons is 4,457,450 shares, representing 5.1% of the class.
• The filing is dated September 24, 2026, with the report signed on October 1, 2026.
• The percentage of ownership is based on 88,173,762 shares of Common Stock outstanding as of July 28, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting a change in beneficial ownership without significant new strategic or financial information.

Positives

• Significant institutional investor (Paradigm BioCapital) has taken a notable stake in Spyre Therapeutics, indicating confidence in the company's prospects.
• The filing clearly delineates the reporting persons and their respective roles and ownership structures.

Negatives

• The filing does not provide any new financial performance data or strategic updates for Spyre Therapeutics.
• The information is limited to ownership disclosure, offering no insight into the investment thesis or future plans.

Risks

• The filing does not explicitly mention any risks associated with Spyre Therapeutics or the investment.
• Potential for increased market activity or volatility due to the disclosure of a significant ownership stake.

Future Outlook

No forward-looking statements or guidance are provided in this Schedule 13G filing.

Management Comments

• Each Reporting Person disclaims beneficial ownership with respect to any Common Stock other than the Common Stock directly beneficially owned by such Reporting Person.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors crossing certain ownership thresholds. This filing indicates Paradigm BioCapital's increased interest in Spyre Therapeutics, a company likely operating in the biotechnology or pharmaceutical sector, given its name and typical SEC filings from such entities.

Comparison to Industry Standards

• This filing is a standard Schedule 13G, which is the typical disclosure for passive investors exceeding a 5% ownership threshold in a publicly traded company.
• The 5.1% ownership stake is a significant but not controlling interest, common for investment funds in the biotechnology sector.

Stakeholder Impact

• Shareholders: May view the increased institutional interest positively, potentially leading to increased trading volume or price movement.
• Management: May need to engage with Paradigm BioCapital regarding their investment thesis and future plans for Spyre Therapeutics.

Next Steps

• Continued monitoring of Paradigm BioCapital's stake and any future filings related to Spyre Therapeutics.
• Further analysis of Spyre Therapeutics' business operations and financial health through their regular SEC filings (e.g., 10-Q, 10-K).

Key Dates

Keywords

Spyre Therapeutics, Paradigm BioCapital, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Investment Management